Cargando…
Diagnosis and clinical severity markers of bullous pemphigoid
The use of a broad spectrum of novel detection systems for autoantibodies to the basement membrane proteins BP180 and BP230 has greatly facilitated the diagnosis of bullous pemphigoid, which most likely explains its increasing incidence in central Europe. Because the pathogenic relevance of antibodi...
Autores principales: | , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Medicine Reports Ltd
2009
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2920699/ https://www.ncbi.nlm.nih.gov/pubmed/20948767 http://dx.doi.org/10.3410/M1-15 |
_version_ | 1782185303231954944 |
---|---|
author | Schmidt, Enno Zillikens, Detlef |
author_facet | Schmidt, Enno Zillikens, Detlef |
author_sort | Schmidt, Enno |
collection | PubMed |
description | The use of a broad spectrum of novel detection systems for autoantibodies to the basement membrane proteins BP180 and BP230 has greatly facilitated the diagnosis of bullous pemphigoid, which most likely explains its increasing incidence in central Europe. Because the pathogenic relevance of antibodies to human BP180 has been convincingly shown both in vitro and in vivo, repeated testing for these antibodies appears to be helpful in guiding treatment decisions during the course of the disease. |
format | Text |
id | pubmed-2920699 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2009 |
publisher | Medicine Reports Ltd |
record_format | MEDLINE/PubMed |
spelling | pubmed-29206992010-10-14 Diagnosis and clinical severity markers of bullous pemphigoid Schmidt, Enno Zillikens, Detlef F1000 Med Rep Review Article The use of a broad spectrum of novel detection systems for autoantibodies to the basement membrane proteins BP180 and BP230 has greatly facilitated the diagnosis of bullous pemphigoid, which most likely explains its increasing incidence in central Europe. Because the pathogenic relevance of antibodies to human BP180 has been convincingly shown both in vitro and in vivo, repeated testing for these antibodies appears to be helpful in guiding treatment decisions during the course of the disease. Medicine Reports Ltd 2009-02-24 /pmc/articles/PMC2920699/ /pubmed/20948767 http://dx.doi.org/10.3410/M1-15 Text en © 2009 Medicine Reports Ltd http://creativecommons.org/licenses/by-nc/3.0/legalcode This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. You may not use this work for commercial purposes |
spellingShingle | Review Article Schmidt, Enno Zillikens, Detlef Diagnosis and clinical severity markers of bullous pemphigoid |
title | Diagnosis and clinical severity markers of bullous pemphigoid |
title_full | Diagnosis and clinical severity markers of bullous pemphigoid |
title_fullStr | Diagnosis and clinical severity markers of bullous pemphigoid |
title_full_unstemmed | Diagnosis and clinical severity markers of bullous pemphigoid |
title_short | Diagnosis and clinical severity markers of bullous pemphigoid |
title_sort | diagnosis and clinical severity markers of bullous pemphigoid |
topic | Review Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2920699/ https://www.ncbi.nlm.nih.gov/pubmed/20948767 http://dx.doi.org/10.3410/M1-15 |
work_keys_str_mv | AT schmidtenno diagnosisandclinicalseveritymarkersofbullouspemphigoid AT zillikensdetlef diagnosisandclinicalseveritymarkersofbullouspemphigoid |